Esperion Therapeutics (ESPR) Other Accumulated Expenses (2012 - 2023)

Esperion Therapeutics' Other Accumulated Expenses history runs 12 years deep, the most recent figure standing at $25.0 million for Q4 2023.

• Quarterly Other Accumulated Expenses rose 89.32% year-over-year to $25.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $25.0 million (up 89.32% YoY) and the FY2023 annual result came in at $25.0 million, up 89.32% from the prior year.
• Other Accumulated Expenses was $25.0 million for Q4 2023 at Esperion Therapeutics, up from $13.2 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $30.4 million in Q4 2021 and bottomed at $3.2 million in Q1 2020.
• A 5-year average of $13.0 million and a median of $10.9 million in 2019 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2019 — Other Accumulated Expenses surged 3910.47% — and 2022, when it slumped 56.58%.
• Esperion Therapeutics' Other Accumulated Expenses stood at $11.9 million in 2019, then surged by 108.83% to $24.8 million in 2020, then climbed by 22.67% to $30.4 million in 2021, then slumped by 56.58% to $13.2 million in 2022, then soared by 89.32% to $25.0 million in 2023.
• Business Quant data shows ESPR's Other Accumulated Expenses at $25.0 million in Q4 2023, $13.2 million in Q4 2022, and $30.4 million in Q4 2021.